Retatrutide Side Effects — Laboratory Research Reference

*Reported tolerability of the triple GIP/GLP-1/glucagon agonist retatrutide across published Phase 2 data: dose-related GI adverse events, heart-rate effects, and titration considerations referenced for research context.*

Research Use Only. All material on this page is provided strictly for in vitro and in vivo laboratory research purposes. It is not medical advice and is not intended for human or veterinary therapeutic use. Researchers are responsible for compliance with all applicable laws, IRB/IACUC oversight and institutional biosafety policy.

Overview

Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist still in late-phase development. The published Phase 2 obesity trial (Jastreboff et al., NEJM 2023) provides the largest tolerability dataset to date.

Adverse-Event Frequency Reference (Phase 2, 48 weeks)

• Nausea: ~36% at 12 mg vs ~13% placebo
• Diarrhea: ~28% at 12 mg vs ~12% placebo
• Vomiting: ~24% at 12 mg vs ~3% placebo
• Constipation: ~20% at 12 mg vs ~9% placebo
• Discontinuation for AE: ~16% at 12 mg vs ~3% placebo — higher than approved GLP-1 / GIP-GLP-1 agents
• Heart rate: mean increase ~7 bpm at 12 mg — larger than GLP-1 class signal, attributed to the glucagon arm
• Hepatic enzymes: small, transient ALT elevations reported, not associated with bilirubin rises
• Pancreatic / thyroid: no excess signals at the Phase 2 sample size; long-term carcinogenicity data pending

Mechanistic Context

Glucagon receptor agonism contributes to energy expenditure and lipolysis but is also implicated in the larger heart-rate effect and the transient transaminitis. Aggressive titration (every 4 weeks) appears important to mitigate GI dropout, mirroring the GLP-1 class.

Laboratory Markers To Track

• Heart rate / BP (priority)
• ALT, AST, bilirubin
• Fasting glucose, HbA1c, fasting glucagon
• Lipid panel (TG, LDL-c)
• Body composition (DEXA in clinical trials)

Practical Research Considerations

Researchers should not assume retatrutide safety equivalence with semaglutide or tirzepatide. The glucagon component changes the hemodynamic profile and likely the hepatic substrate-handling profile. Pre-specify HR/BP and LFT sampling.

Frequently Asked Research Questions

Why does retatrutide raise heart rate more than tirzepatide?

Glucagon receptor activation increases sympathetic tone and energy expenditure; the published mean HR increase at the 12 mg Phase 2 dose was approximately 7 bpm — roughly double the GLP-1 class signal.

Have any cases of serious hepatic injury been reported?

No DILI cases were reported in the Phase 2 trial. Transient ALT elevations without bilirubin involvement were observed; Phase 3 long-term hepatic monitoring is ongoing.

What is the dropout rate in trials?

Approximately 16% at the 12 mg dose discontinued for adverse events in the 48-week Phase 2 trial — higher than approved incretin agents and driven largely by GI events.

References

1. Drucker DJ. *Mechanisms of action and therapeutic application of GLP-1.* Cell Metab. 2018.

1. Frias JP, et al. *Tirzepatide vs semaglutide once weekly.* N Engl J Med. 2021.

1. Jastreboff AM, et al. *Triple–hormone-receptor agonist retatrutide for obesity.* N Engl J Med. 2023.

1. Sikiric P, et al. *Stable gastric pentadecapeptide BPC 157 — review.* Curr Pharm Des. 2018.

1. Goldman MP. *Photoprotection and α-MSH analogues.* J Drugs Dermatol. 2010.

1. Teichman SL, et al. *Prolonged stimulation of GH and IGF-1 secretion by CJC-1295.* J Clin Endocrinol Metab. 2006.

1. Goldstein AL, Hannappel E. *Thymosin β4 — actin sequestering and tissue repair.* Ann N Y Acad Sci. 2007.

1. Pickart L, Margolina A. *Regenerative and protective actions of the GHK-Cu peptide.* Int J Mol Sci. 2018.